Asia Pacific

Refine Search

Alzheimer’s drug Leqembi launched in China

Alzheimer’s Leqembi, Launched , China 28 June 2024

UCB’s epilepsy drug Briviact cleared in Japan

26 June 2024

Chinese approval unlocks huge new market for Wegovy

Danish drugmaker Novo Nordisk’s GLP-1 receptor agonist Wegovy (semaglutide) has been approved in China for long-term weight management. 26 June 2024

Tagrisso plus chemo approved in Japan as new first-line therapy

25 June 2024

First treatment to address underlying pathophysiology of XLH backed by NICE

First treatment to address underlying pathophysiology of XLH backed by NICE 21 June 2024

Grifols forges strategic alliance with Haier Group

Grifols forges strategic alliance with Haier Group 20 June 2024

Dizal scores a first with golidocitinib approval in China

Dizal scores a first with golidocitinib approval in China 20 June 2024

Otsuka expands licensing deal for donidalorsen

Otsuka expands licensing deal for donidalorsen 20 June 2024

New data on Radicava for people with ALS presented at ENCALS

New data on Radicava for people with ALS presented at ENCALS 18 June 2024

Takeda’s epilepsy drug soticlestat misses Phase III endpoints

Takeda’s epilepsy drug soticlestat misses Phase III endpoints 17 June 2024

FDA slaps clinical hold on MediLink/BioNTech’s ADC drug trial

FDA slaps clinical hold on MediLink/BioNTech’s ADC drug trial 17 June 2024

Argatroban business in Europe transferred to Ethypharm

Argatroban business in Europe transferred to Ethypharm 17 June 2024

Fiocruz and Sinovac announce cooperation in vaccine R&D

Fiocruz and Sinovac announce cooperation in vaccine R&D 17 June 2024

Takeda signs olverembatinib option agreement with Ascentage

Japanese drugmaker Takeda (TYO: 4502) has signed an option agreement with China’s Ascentage Pharma (HKG: 6855) to enter into an exclusive license agreement for 14 June 2024

China's Innovent holds potential to change pancreatic cancer treatment landscape, says analyst

China's Innovent holds potential to change pancreatic cancer treatment landscape, says analyst 14 June 2024

Samsung Bioepis touts Phase III results for Epysqli at EHA

Samsung Bioepis touts Phase III results for Epysqli at EHA 14 June 2024

Abbvie and FutureGen team up on IBD drug

US drugmaker AbbVie and China’s FutureGen Biopharmaceutical have announced a license agreement to develop FG-M701, a next generation TL1A antibody for the treat 13 June 2024

Chinese acceptance of zanidatamab filing

The Center for Drug Evaluations of the National Medical Products Administration (NMPA) in China has accepted the biologics license application (BLA) for zanidat 11 June 2024

Kyowa Kirin to invests in expanding US biologics manufacturing

Kyowa Kirin to invests in expanding US biologics manufacturing 11 June 2024

BIOSECURE Act forces US pharma to re-evaluate China manufacturing reliance

BIOSECURE Act forces US pharma to re-evaluate China manufacturing reliance 10 June 2024

12 3 4 5 6 7 8 9 10 Next page

Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze